S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
Log in
(Ad)
Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, Forecast & News

$99.00
-1.74 (-1.73 %)
(As of 01/22/2020 04:00 PM ET)
Today's Range
$98.25
Now: $99.00
$102.06
50-Day Range
$100.74
MA: $115.85
$124.10
52-Week Range
$56.76
Now: $99.00
$131.87
Volume773,567 shs
Average Volume699,585 shs
Market Capitalization$3.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$179.80 million
Book Value$0.64 per share

Profitability

Net Income$-309,240,000.00
Net Margins-143.09%

Miscellaneous

Employees483
Market Cap$3.24 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

A U.S. congressional committee passed important legislation that enables each state to set its own policies around cannabis… This bill also allows states to expunge federal marijuana convictions and arrests. This will likely lead to federal legalization sooner than expected. Get in early and you just might be the next 'Marijuana Millionaire'...

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) released its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($2.59) EPS for the quarter, missing the Zacks' consensus estimate of ($2.35) by $0.24. The biopharmaceutical company had revenue of $61.95 million for the quarter, compared to analyst estimates of $63.89 million. Intercept Pharmaceuticals had a negative return on equity of 495.47% and a negative net margin of 143.09%. The company's revenue for the quarter was up 31.8% compared to the same quarter last year. During the same period last year, the firm earned ($2.18) EPS. View Intercept Pharmaceuticals' Earnings History.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Intercept Pharmaceuticals.

What price target have analysts set for ICPT?

20 Wall Street analysts have issued 1 year target prices for Intercept Pharmaceuticals' stock. Their forecasts range from $68.00 to $257.00. On average, they anticipate Intercept Pharmaceuticals' stock price to reach $145.79 in the next twelve months. This suggests a possible upside of 47.3% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.

What is the consensus analysts' recommendation for Intercept Pharmaceuticals?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Intercept’s lead drug Ocaliva’s performance has been strong in the year so far. Management’s efforts to increase awareness about the label update of the drug in 2018 and expand sales force across the United States, thereafter, are yielding results. Solid growth in patient enrollment is likely to drive the company’s performance. Meanwhile, Intercept is working to expand the drug’s label in the promising NASH space. While the failure of Gilead’s late-stage study on selonsertib in patients suffering from compensated cirrhosis due to NASH puts Intercept ahead in the race, additional results from the REGENERATE study in NASH were mixed and did not impress investors. Nevertheless, a potential approval in this indication will significantly boost growth. However, shares have underperformed the industry in the year so far." (10/14/2019)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating on ICPT after the company reported a slight 2Q19 beat on Ocaliva revenues, which appear to have been aided by a benefit in channel inventories. With that said, our thesis remains unchanged and we think there are too many unknown variables in terms of OCA’s potential adcom/approval and launch in NASH for us to be comfortable recommending the stock here. Management remains on track to file its NDA for OCA in NASH by the end of this quarter followed by its MAA filing in the EU in 4Q19. We think investor focus remains on the potential for OCA in NASH and in particular: whether or not ICPT’s filing of a NDA for OCA in NASH (rather than a sNDA) can lead to bi- furcated/indication based pricing, potential payer/reimbursement dynamics in the NASH category and the use of non-invasive biomarkers vs. biopsy for diagnosis." (8/12/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $170 PT. Positive Ph3 data on fibrosis de-risk this binary readout. Intercept announced this morning that the 25mg dose hit on one of the key endpoints, which is a one point change in fibrosis stage (OCA 23.1%, placebo 11.9%, p-value=0.0002). They saw a numerical trend on NASH resolution in the 25mg. Although this endpoint did not hit (25mg p-value=0.1268), we believe that the data profile for OCA will support approval; fibrosis is relevant for potential liver outcomes. Since there was a p-value of 0.0013 when F1 co-morbidities were added, we are interested to see more analysis around NASH resolution." (2/19/2019)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

News articles about ICPT stock have trended neutral recently, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Intercept Pharmaceuticals earned a news impact score of 0.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the near term. View News Stories for Intercept Pharmaceuticals.

Are investors shorting Intercept Pharmaceuticals?

Intercept Pharmaceuticals saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 4,540,000 shares, a drop of 13.5% from the December 15th total of 5,250,000 shares. Based on an average daily trading volume, of 630,900 shares, the short-interest ratio is presently 7.2 days. Currently, 18.0% of the shares of the stock are short sold. View Intercept Pharmaceuticals' Current Options Chain.

Who are some of Intercept Pharmaceuticals' key competitors?

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Micron Technology (MU), Biogen (BIIB) and Celgene (CELG).

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:
  • Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 51)
  • Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 49)
  • Mr. Jerome B. Durso, Chief Operating Officer (Age 51)
  • Mr. Ryan T. Sullivan, Gen. Counsel & Sec. (Age 43)
  • Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance (Age 57)

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.27%), Rhenman & Partners Asset Management AB (0.12%), Tributary Capital Management LLC (0.04%), Assenagon Asset Management S.A. (0.03%), Janney Montgomery Scott LLC (0.02%) and Wedbush Securities Inc. (0.01%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David A Ford, David Shapiro, Francesco Micheli, Gail Cawkwell, Jason Campagna, Keith Michael Gottesdiener, Lisa Bright, Luca Benatti, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, SPA Genextra and Srinivas Akkaraju. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Which major investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, Wedbush Securities Inc., Janney Montgomery Scott LLC and Larson Financial Group LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David A Ford, David Shapiro, Gail Cawkwell, Jason Campagna, Lisa Bright, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan and Srinivas Akkaraju. View Insider Buying and Selling for Intercept Pharmaceuticals.

Which major investors are buying Intercept Pharmaceuticals stock?

ICPT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Tributary Capital Management LLC, Raymond James Trust N.A., NEXT Financial Group Inc, Nisa Investment Advisors LLC and Kistler Tiffany Companies LLC. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener, Luca Benatti, Mark Pruzanski and Srinivas Akkaraju. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $99.00.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $3.24 billion and generates $179.80 million in revenue each year. The biopharmaceutical company earns $-309,240,000.00 in net income (profit) each year or ($10.86) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe.View Additional Information About Intercept Pharmaceuticals.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is http://www.interceptpharma.com/.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  976 (Vote Outperform)
Underperform Votes:  588 (Vote Underperform)
Total Votes:  1,564
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: Cryptocurrencies

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel